News Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Oct. 10, 2002--Agilent Technologies Inc. (NYSE:A) today announced that it has obtained a license from Millennium Pharmaceuticals Inc. (Nasdaq:MLNM) that will allow Agilent to exclusively develop and sell software based on Millennium's SpectrumMill software. SpectrumMill software is a package of tools developed and used internally at Millennium for scientists doing protein research for disease and drug discovery. The agreement also will provide Millennium with early and advanced access to Agilent products and chemistries for proteomics research.

SpectrumMill software provides scientists with highly advanced tools for analyzing large volumes of complex mass spectral data. SpectrumMill data can be integrated into Agilent's recently introduced Synapsia Informatics Workbench software platform.

"We look forward to offering our customers the SpectrumMill software," said John Michnowicz, proteomics program manager at Agilent. "We believe it will greatly increase the amount of information that scientists using Agilent's mass spectrometry-based proteomics solutions can extract from their samples."

Millennium will assist in the development and evaluation of future Agilent proteomics products. Agilent hopes to benefit from Millennium's early evaluation of its proteomics products in an advanced research setting.

"We are very pleased that SpectrumMill will now become widely available to the proteomics and mass spectrometry communities," said Steven A. Carr, senior director of Discovery Technologies at Millennium. "In addition, the collaborative components of this agreement will provide Millennium early and advanced access to proteomics innovations under development by Agilent, which will contribute to enhancing our productivity and advancing our pipeline of drug candidates."

SpectrumMill's Advanced Mass Spectral Analysis Features

SpectrumMill software combines data analysis functions essential to advanced proteomics research and data management tools for handling enormous sample volumes. Major features include:

• spectral preprocessing and protein database searching for both MS and MS/MS data, including peptide mass fingerprinting and MS/MS search modes and support for accurate mass data;

• quantitative analysis through isotope labeling such as ICAT;

• de novo sequencing;

• configurable multi-experiment summary reports that facilitate complex studies such as differential expression comparisons;

• extensive toolset for result validation and state tracking, with linkage to the raw MS data supporting each summary element; and

• support for spectral analysis from most major instrument vendors.

In addition, the SpectrumMill software includes output features to make the protein data more meaningful to biologists and biochemists.

Information about Agilent's life science products and services is available at www.agilent.com/chem.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global technology leader in communications, electronics and life sciences. The company's 37,000 employees serve customers in more than 120 countries. Agilent had net revenue of $8.4 billion in fiscal year 2001. Information about Agilent is available on the Web at www.agilent.com.

This news release contains forward-looking statements (including, without limitation, statements relating to Millennium's evaluation and development of future Agilent proteomics products, Agilent's expectation to benefit from Millennium's early evaluation of its proteomics products, Agilent's ability to integrate the software into its current and future MS-based proteomics solutions, that the SpectrumMill software will greatly increase the amount of information that scientists using Agilent's MS and LC/MS solutions for proteomics can extract from their samples, and the expectation that Agilent will continue to expand the features in SpectrumMill) that involve risks and uncertainties that could cause results of Agilent Technologies to differ materially from management's current expectations. These risks are detailed in reports filed with the Securities and Exchange Commission, including Agilent's Annual Report on Form 10-K/A filed Feb. 1, 2002, and its Quarterly Report on Form 10-Q for the quarter ended April 30, 2002.

NOTE TO EDITORS: Sales information is available by calling an Agilent Technologies sales office listed in the telephone directory white pages. Please do NOT use editor contact or corporate telephone numbers.

Press releases, photography and other information can be accessed and downloaded from the Agilent Technologies Life Sciences and Chemical Analysis newsrooms at www.agilent.com/about/newsroom/lifesciences/ and www.agilent.com/about/newsroom/chemical/.

Information in this news release applies specifically to products available in the United States. Product availability, pricing and specifications may vary in non-U.S. markets.

If you choose to review this item, your readers will receive the quickest response to their inquiries by e-mailing them to carol_dunn@agilent.com.

Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.

--30--nj/sf*